Support to the market growth comes from shift towards increased safety standards & compliance with more stringent regulatory requirements. Healthcare practitioners are rapidly incorporating filter ...
WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...
The MarketWatch News Department was not involved in the creation of this content. This transformative device advances safety and efficiency in drug preparation, underscoring the startup's journey from ...
Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...
Apellis Pharmaceuticals Inc. shares APLS jumped 30% premarket on Wednesday after the company identified a potential cause for a rare but serious side effect linked with its Syfovre injection for ...
The US Food and Drug Administration (FDA) has approved ranibizumab injection (Lucentis, Genentech) in a prefilled syringe, the company has announced. Like the Lucentis 0.5 mg vial, the 0.5 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback